In this study, hydroxamate-based (<b>3a</b>) and benzamide-based (<b>6a</b>) HDAC inhibitors were synthesized and evaluated in glioma cell lines and glioblastoma stem cells (GSC). The gene discussed is HDAC9; the disease is central nervous system cancer.